1. JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Issue 1 (3rd September 2021) Authors: Ramalingam, Suresh S.; Thara, Eddie; Awad, Mark M.; Dowlati, Afshin; Haque, Basir; Stinchcombe, Thomas E.; Dy, Grace K.; Spigel, David R.; Lu, Sharon; Iyer Singh, Nithya; Tang, Yongqiang; Teslenko, Iryna; Iannotti, Nicholas Journal: Cancer Issue: Volume 128:Issue 1(2022) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗